Inventiva AI Stock Analysis
Inventiva (6IVA) AI Stock Analysis
Inventiva
(Frankfurt:6IVA)
No summary available
Inventiva (6IVA) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 191.29M
- Dividend Yield
- ―
- Average Volume (3M)
- 1,283
- Price to Earnings (P/E)
- -6.4
- Beta (1Y)
- 1.03
- Revenue Growth
- -99.64%
- EPS Growth
- 68.67%
- Country
- Germany
- Employees
- 77
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Inventiva Business Overview & Revenue Model
Company Description
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepa...
Inventiva Earnings Call Summary
The call was strongly focused on progress toward the NATiV3 phase III readout, positive phase II-B efficacy, preparation for potential regulatory and commercial milestones, and a strengthened financial position. Management also addressed known tolerability considerations, including weight gain, edema, and hemoglobin decline, while withholding additional blinded phase III safety and efficacy details. The positive development, financing, and preparation updates significantly outweighed the disclosed challenges and uncertainties.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Inventiva remains on track to report NATiV3 top-line data in the fourth quarter of 2026 after the last patient completed their final 72-week visit; the main cohort enrolled 1,009 participants with F2 or F3 fibrosis, and the trial was powered at 90%. Subject to positive phase III results, the company intends to file an NDA with the FDA in the first half of 2027, seek accelerated approval with the FDA and conditional approval with the EMA, and pursue a potential U.S. commercial launch in 2028; current financing provides cash runway until the end of the second quarter of 2027, extending to the start of the first quarter of 2028 assuming full exercise of Tranche 3 warrants and successful completion of Tranche C, while the company expects to initiate a confirmatory outcomes trial in cACLD and has not provided guidance on NATiV3 top-line details, edema over time, or future raises.
Inventiva Risk Analysis
Inventiva disclosed 83 risk factors in its most recent earnings report. Inventiva reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
1 New RiskInventiva Peers Comparison
Overall Rating
IOVA51Neutral
KURA48Neutral
MRVI48Neutral
URGN43Neutral
MBX34Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | $3.59B | -14.64 | -29.71% | ― | 51.31% | 56.78% | |
| 48Neutral | $713.90M | -2.35 | -336.24% | ― | -23.76% | -33.09% | |
| 48Neutral | $1.96B | -16.92 | -31.86% | ― | 10.77% | 46.91% | |
| 43Neutral | $1.28B | -19.83 | 53.97% | ― | 159.29% | 61.62% | |
| 34Underperform | $2.78B | -18.28 | -34.35% | ― | ― | -27.83% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:6IVA | Inventiva SA ADR | 3.46 | 0.04 | 1.17% | |
| IOVA | Iovance Biotherapeutics | 7.76 | 5.34 | 220.66% | |
| KURA | Kura Oncology | 7.77 | -3.08 | -28.39% | |
| URGN | Urogen Pharma | 26.18 | 2.48 | 10.46% | |
| MRVI | Maravai Lifesciences Holdings, Inc. | 7.54 | 4.20 | 125.75% | |
| MBX | MBX Biosciences, Inc. | 55.94 | 30.33 | 118.43% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
